Clinical Trials Directory

Trials / Completed

CompletedNCT06084650

Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients

OCT and OCTA Deep Learning in Waldenström's Macroglobulinemia Patients

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Federico II University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

This study evaluates the ability of deep learning to improve the knowledge about structural and vascular retinal changes in Waldenström's Macroglobulinemia patients, using optical coherence tomography angiography.

Detailed description

Waldenstrom macroglobulinemia (mak-roe-glob-u-lih-NEE-me-uh) is a rare type of cancer that begins in the white blood cells. The optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features. The study evaluates the changes in optical coherence tomography angiography features in Waldenstrom macroglobulinemia, elaborating these data with artificial intelligence.

Conditions

Timeline

Start date
2023-01-01
Primary completion
2023-09-30
Completion
2023-10-01
First posted
2023-10-16
Last updated
2024-05-22

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06084650. Inclusion in this directory is not an endorsement.

Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients (NCT06084650) · Clinical Trials Directory